悦达国际控股(00629.HK) 公布,与深圳精科生物技术订立条款清单,拟透过注资及收购成都诺医德医学检验实验室合共52%股权,后者主要从事类器官技术的开发及类器官技术在肿瘤精准医学的应用,代价共约5,200万人民币。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.